Getinge to further streamline its operations and submits an updated earnings outlook for the 2009 financial year

Getinge to further streamline its operations and submits an updated earnings
outlook for the 2009 financial year 

Getinge, 14 January 2010

During the fourth quarter of 2009, the Getinge Group will be posting additional
provisions for planned restructuring activities in addition to the amount
previously announced. Restructuring costs in the fourth quarter of 2009 will
total SEK 193 million. Of this amount, SEK 84 million pertains primarily to the
integration of Datascope and the Cardiac and Vascular Divisions for which, as
planned, SEK 227 million will be charged against profit for the year. The
remaining SEK 109 million provision for restructuring activities in the fourth
quarter pertains to new and additional activities in the Infection Control and
Extended Care business areas. 

In line with Infection Control's manufacturing strategy, the intention is to
discontinue production at the unit in Peiting, Germany, and to relocate portions
of the production concerned to the business area's unit in Växjö, Sweden. The
business area also intends to discontinue production in Lynge, Denmark, and
transfer this to Getinge, Sweden. Consultation with the employees involved and
trade union representatives has been initiated. The costs for the planned
activities amount to approximately SEK 85 million and are expected to result in
annual savings of approximately SEK 40 million, effective from 2011. 

Within Extended Care, discussions have been initiated with appropriate employee
representatives concerning the merger of the business area's two sales companies
in France. Costs for merging the two sales companies are estimated at SEK 24
million, which will result in annual profit increases of SEK 15 million from
2011. 

Taking into account the additional restructuring costs of approximately SEK 109
million that will be charged against the 2009 financial year, it is the Group's
assessment that the year's pre-tax profit will slightly exceed SEK 2,600
million, which is a significant improvement compared with the earnings outlook
submitted at Getinge's Capital Markets Day on 4 December.  


For further information: 
Johan Malmquist, CEO
Ulf Grunander, CFO
+46 (0)35-15 55 00

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions and intensive care.



Informationen är sådan som Getinge AB är skyldigt att offentliggöra enligt lagen
om värdepappersmarknaden och/eller lagen om handel med finansiella instrument.